This application requests funding to acquire a Q-TOF mass spectrometer to replace the mass spectrometer component of an 18-year-old Bruker Esquire-LC/MS system, which is an essential part of the Shared Instrument Facility in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC). The Bruker Esquire-LC/MS system has been well maintained and is the work horse supporting extensive small-molecular drug discovery and drug delivery programs at UTHSC in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection, and inflammation diseases. Several small-molecule drug candidates have been licensed for commercial development, including one currently in Phase III clinical trials. However, the age of the current mass spectrometer has resulted in more and more frequent breakdowns in recent years. Bruker officially stopped technical support for this type of instrument system in early 2010. Repair parts are scarce and have become very expensive. The proposed new Q-TOF mass spectrometer will replace the now unreliable mass spectrometer component of the Bruker Esquire-LC/MS system. This powerful new mass spectrometer will benefit more than 10 principal investigators supported by nine R01s, one RC2, one R33, three R21s, and other sources of support. The Q-TOF mass spectrometer will provide years of reliable accessibility, greater sensitivity in both MS and MS/MS modes, and the capability to obtain accurate mass for more efficient structure elucidation. This state-of-the-art instrument wil support drug discovery in preclinical development by using novel small molecules and their translation to innovative therapies for a variety of diseases. UTHSC is strongly committed to supporting biomedical research. The College of Pharmacy will provide $25,000 as a cost share for the purchase of the new instrument, fully support a staff scientist to maintain the Shared Instrument Facility, and assume all future maintenance and repair cost after the warranty period without charging user fees. An advisory committee will ensure effective utilization of the instrument and adequate access by the major users, other NIH-supported investigators, new investigators, and investigators with early-stage projects.
The Q-TOF mass spectrometer requested will replace a technologically limited Esquire-LC/MS mass spectrometer that is nearly two decades old and will provide reliable and sophisticated support for 20 currently funded projects important to human health. These projects focus on small-molecule drug discovery and drug delivery in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection and inflammation diseases.
|Wang, Qinghui; Arnst, Kinsie E; Xue, Yi et al. (2018) Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. Eur J Med Chem 149:211-224|
|Tuckey, Robert C; Li, Wei; Ma, Dejian et al. (2018) CYP27A1 acts on the pre-vitamin D3 photoproduct, lumisterol, producing biologically active hydroxy-metabolites. J Steroid Biochem Mol Biol 181:1-10|
|Banerjee, Souvik; Arnst, Kinsie E; Wang, Yuxi et al. (2018) Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy. J Med Chem 61:1704-1718|
|Lin, Zongtao; Marepally, Srinivasa R; Goh, Emily S Y et al. (2018) Investigation of 20S-hydroxyvitamin D3 analogs and their 1?-OH derivatives as potent vitamin D receptor agonists with anti-inflammatory activities. Sci Rep 8:1478|
|Slominski, Andrzej T; Bro?yna, Anna A; Skobowiat, Cezary et al. (2018) On the role of classical and novel forms of vitamin D in melanoma progression and management. J Steroid Biochem Mol Biol 177:159-170|
|Wang, Qinghui; Arnst, Kinsie E; Wang, Yuxi et al. (2018) Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities. J Med Chem 61:7877-7891|
|Slominski, Andrzej T; Kim, Tae-Kang; Hobrath, Judith V et al. (2017) Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols. Sci Rep 7:11434|
|Slominski, Andrzej T; Kim, Tae-Kang; Hobrath, Judith V et al. (2017) Endogenously produced nonclassical vitamin D hydroxy-metabolites act as ""biased"" agonists on VDR and inverse agonists on ROR? and ROR?. J Steroid Biochem Mol Biol 173:42-56|
|Lin, Zongtao; Chen, Hao; Belorusova, Anna Y et al. (2017) 1?,20S-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis. Sci Rep 7:10193|
|Lin, Zongtao; Marepally, Srinivasa R; Ma, Dejian et al. (2016) Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23S-Dihydroxyvitamin D3 and Its 23R Epimer. J Med Chem 59:5102-8|
Showing the most recent 10 out of 42 publications